Analytical Data
-
Gene name
Smad7
- Application
-
Alternative Names
MADH7; MADH8; Mothers against DPP homolog 8
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O15105
-
Expression Region
Trp261~Arg426
-
Molecular Weight
23kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Smad7 is an important regulatory protein involved in the transforming growth factor-beta (TGF-β) signaling pathway, which plays a crucial role in various cellular processes, including cell growth, differentiation, and immune response. Elevated levels of TGF-β are associated with fibrosis, cancer progression, and various inflammatory diseases, making Smad7 a potential therapeutic target. As an inhibitory Smad, Smad7 disrupts the TGF-β signaling by preventing the phosphorylation of receptor-regulated Smads (R-Smads), thus downregulating fibrosis and tumorigenesis processes. Research into recombinant Smad7 protein focuses on its potential applications in treating fibrotic diseases, autoimmune conditions, and cancer, by restoring the balance of TGF-β signaling. Additionally, the ability to produce and purify recombinant Smad7 allows for detailed functional studies and the exploration of its mechanisms of action in various biological contexts. Understanding the role of Smad7 not only provides insights into the intricacies of TGF-β signaling but also opens avenues for novel therapeutic strategies that target pathways involved in disease progression and resolution.
